mammary analogue secretory carcinoma of salivary gland … conf pdfs/23 b - sat case...sweat duct...
TRANSCRIPT
A Cutaneous Facial Mass Identified as the New Entity ‘Mammary Analogue Secretory Carcinoma’ of Probable Salivary Gland Origin
Scott W. Binder, MD Professor and Senior Vice Chair
Chief, Dermatopathology
Geffen/UCLA Healthcare
Case Presentation
A 50 year-old man presents with a 7 mm erythematous papule on the right face
• Developed over a few months
• Asymptomatic
• No history of prior neoplasms including salivary gland tumors
• Lesion located just lateral to nose
Clinical Impression
“Rule out bug bite”
Histopathology
4
Histopathology
5
Histopathology
6
Histopathology
7
Histopathology
8
Histopathology
9
Differential Diagnoses
• Acinic cell carcinoma
• Apocrine or eccrine sweat duct tumor
• Mammary analogue secretory carcinoma
• Benign oncocytic neoplasms
• Mucoepidermoid carcinoma
• Metastasis from a visceral primary
Outside Special Stains
S-100 EMA CK 7
CK 20 p63 Mucicarmine
Additional Immunohistochemistry
Mammaglobin CEA CK 5/6 Thyroglobin
TTF-1 PSA Ki67
Diagnosis
• Mammary Analogue Secretory Carcinoma (MASC) •? Primary salivary gland origin v. primary cutaneous tumor
• Rule out metastasis
Background
• MASC first described in 2010 by Skalova et al.
• Morphologic overlap between acinic cell carcinoma and secretory carcinoma of the breast
• Tumors affect all ages (range 14-77), slightly male-predominant
MASC
• Presents as slowly growing mass, often near parotid gland
• No evidence of primary cutaneous origin, as of yet
• Most treated with non-radical excision +/-radiotherapy
• Cases of lymph node metastases, local recurrences, low mortality Chiosea et al, Histopathology 2012
Histology of MASC
• Unencapsulated, lobulated
• Intercalated duct cells in tubular, microcystic, papillary patterns
• Lumina with ample “bubbly” secretions (mucicarmine +)
• Absence of serous acinar granules
Immunohistochemistry of MASC Staining • Usually positive
•S100
•CK7
•Vimentin • Often positive
• EMA
• GCDFP
• Mammaglobin
• Negative
• CK5/6, CK20
• P63, TTF-1, PSA, Thyroglobulin
17
Immunohistochemistry of most apocrine tumors
• Cytokeratin 5/6+, p63+ • S100+/-, cytokeratin 7+ • Mammaglobin +/-, EMA+ (patchy, highlights ducts) • CEA+, GCDFP 15+/-
18
Key Differential Diagnoses of MASC
Diagnosis Key Cytomorphologic Features
Ancillary Testing Features
Benign oncocytic neoplasms (oncocytoma, oncocytic cystadenoma, Warthin tumor)
Lack vacuolated cytoplasm, more cohesive
S-100 negative, anti-mitochondrial antibody positive
Acinic cell carcinoma Usually lacks mucin PAS-D+ cytoplasmic granules, DOG-1 strongly positive, mammaglobin negative
Mucoepidermoid carcinoma
Epidermoid differentiation p63 positive, S100 negative, MAML2 translocation
Metastatic carcinoma High grade nuclei, many show necrosis
Staining variable
19
Fusion Gene
• Almost all MASC had fusion gene ETV6-NTRK3
Normal Cells No ETV6 Split Signals Abnormal ETV6 split signals
Clinical Course
• Patient had neoplasm completely excised by the ENT service
• Work-up for primary underlying neoplasm is on-going and imaging studies are negative for primary salivary gland tumor
Summary
• MASC is likely an under-recognized diagnosis and can present a diagnostic pitfall, easily being confused with a primary adnexal tumor given that it is a newly-described entity and too bland to be immediately interpreted as a metastasis or recurrence. The origin of this particular tumor is still uncertain, as no salivary gland primary has been detected in this patient.
• Immunohistochemical stains for S100, CK7, p63, cytokeratin 5/6, mammaglobin, and identification of the ETV6-NTRK3 fusion gene would be required to completely evaluate tumors of this type
• ? Primary cutaneous/subcutis MASC v. unusual primary apocrine sweat duct tumor (solid and cystic hidradenoma)
Cutaneous Metastases v. Adnexal Primary Carcinoma: A Practical Approach
23
Cutaneous Metastases
• Clinical Considerations •Mean age at presentation is 62 •Most common primary tumors
• Lung 30% • Melanoma 18% • G.I. Tract 14% • Breast 5% • Lymphoma 5%
•In approximately 10% of cases, the primary is unknown • Histologic Types
•Adenocarcinoma 40% •Melanoma 15% •Squamous carcinoma 15% •Other 30%
24
Cutaneous Metastases v. Primary Adnexal Carcinoma
• Histopathologic Characteristics of Metastases •Tumor growth often concentrated in the deep dermis - “bottom heavy” appearance
•Sparing of epidermis common •Ulceration and pagetoid spread rarely noted (colonic and melanoma)
•Tumor necrosis sometimes present
•Lymph/vascular invasion sometimes observed •High grade tumor cells with numerous mitoses
25
Cutaneous Metastases v. Primary Adnexal Carcinoma
• Immunohistochemical Considerations •Battery may include
•Cytokeratin 7 •Cytokeratin 20 •S-100 •MART-1/Melan-A/MITF or SOX-10 •PSA •TTF-1 •ER/PR/Her-2-neu •CDX-2 •Cytokeratin 5/6, p63*
26
Cutaneous Metastases v. Primary Adnexal Carcinoma
• Recent studies have shown that CK5/6 and p63 may help distinguish primary adnexal neoplasms (CK5/6+/p63+) from most metastatic carcinomas (CK5/6-/p63-)
• P63 especially helpful • D2-40 not been especially helpful in my lab
27
46 yo F with history of breast cancer x7 years
28
Histopathology
29
Histopathology
30
Histopathology
31
IHC Results
32
CK7
IHC Results
33
ER
IHC Results
34
HER2/neu
IHC Results
35
CK5/6
IHC Results
36
P63
68 yo M w paranasal mass present x 1 yr – rapid recent growth
37
Histopathology
38
Histopathology
39
Histopathology
40
IHC Results
41
CK5/6
IHC Results
42
p63
Cutaneous Metastases v. Primary Adnexal Carcinoma
• Impossible to reliably distinguish primary or metastatic eccrine/apocrine tumors from cutaneous metastases of breast carcinomas, especially apocrine or mucinous types
• Immunohistochemical Staining of Breast v. Metastases •ER (estrogen receptor) •PR (progesterone receptor) •GCDFP-15 (gross cystic disease fluid protein) •CEA •Her-2-neu
• None of these may reliably separate primary sweat duct tumors from breast metastases
43
Cutaneous Metastases v. Primary Adnexal Carcinoma
• Aberrant staining of metastases •Technical
•Antibody •Technique
•Therapeutic effect – chemo and/or radiation/immune modulators •Tumor metastases may have different immuno phenotypes than the primary •Tumors don’t always read the books •Another tumor/primary is responsible for the aberrant staining
44
Cutaneous Metastases v. Primary Adnexal Carcinoma
• Take Home •H&E considerations and clinical information most important for diagnostic purposes •Immunohistochemistry stains are useful ancillary studies, especially cytokeratin 5/6 and p63 but be careful as these may lead you astray •Be sure to eliminate the possibility of a basal cell carcinoma demonstrating unusual growth patterns •Always think of the possibility of a primary adnexal CA in the appropriate clinical and histologic context •Occasional inability to differentiate a primary adnexal CA from a visceral metastasis
45
References
• Saliva A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, Starek I, Geierova M, Simpson RH, Passador-Santos F, Ryska A, Leivo I, Kinkor Z, Michal M. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010 May;34(5):599-608.
•Griffith C, Seethala R, Chiosea SI. Mammary analogue secretory carcinoma: a new twist to the diagnostic dilemma of zymogen granule poor acinic cell carcinoma. Virchows Arch. 2011 Jul;459(1):117-8.
• Fehr A, Löning T, Stenman G. Mammary analogue secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion. Am J Surg Pathol. 2011 Oct;35(10):1600-2.
•Rastatter JC, Jatana KR, Jennings LJ, Melin-Aldana H. Mammary analogue secretory carcinoma of the parotid gland in a pediatric patient. Otolaryngol Head Neck Surg. 2012 Mar;146(3):514-5.
•Connor A, Perez-Ordoñez B, Shago M, Skálová A, Weinreb I. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol. 2012 Jan;36(1):27-34.
•Chiosea SI, Griffith C, Assaad A, Seethala RR. Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology. 2012 Sep;61(3):387-94.
•Griffith CC, Stelow EB, Saqi A, Khalbuss WE, Schneider F, Chiosea SI, Seethala RR. The cytological features of mammary analogue secretory carcinoma: a series of 6 molecularly confirmed cases. Cancer Cytopathol. 2013 May;121(5):234-41.
•Bishop JA. Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head Neck Pathol. 2013 Mar;7(1):35-9.
References
• Jung MJ, Song JS, Kim SY, Nam SY, Roh JL, Choi SH, Kim SB, Cho KJ. Finding and characterizing mammary analogue secretory carcinoma of the salivary gland. Korean J Pathol. 2013 Feb;47(1):36-43.
•Hwang MJ, Wu PR, Chen CM, Chen CY, Chen CJ. A rare malignancy of the parotid gland in a 13-year-old Taiwanese boy: case report of a mammary analogue secretory carcinoma of the salivary gland with molecular study. Med Mol Morphol. 2013 Aug 18.
•Knezevich SR, Garnett MJ, Pysher TJ, et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 1998;15:5046–5048.
•Makretsov N, He M, Hayes M, et al. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer. 2004;40:152–157.
•Rastatter JC, Jatana KR, Jennings LJ, Melin-Aldana H. Mammary analogue secretory carcinoma of the parotid gland in a pediatric patient. Otolaryngol Head Neck Surg. 2012 Mar;146(3):514-5.
•Connor A, Perez-Ordoñez B, Shago M, Skálová A, Weinreb I. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol. 2012 Jan;36(1):27-34.
•Chiosea SI, Griffith C, Assaad A, Seethala RR. Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology. 2012 Sep;61(3):387-94.
References
•Griffith CC, Stelow EB, Saqi A, Khalbuss WE, Schneider F, Chiosea SI, Seethala RR. The cytological features of mammary analogue secretory carcinoma: a series of 6 molecularly confirmed cases. Cancer Cytopathol. 2013 May;121(5):234-41.
•Bishop JA. Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head Neck Pathol. 2013 Mar;7(1):35-9.
•Jung MJ, Song JS, Kim SY, Nam SY, Roh JL, Choi SH, Kim SB, Cho KJ. Finding and characterizing mammary analogue secretory carcinoma of the salivary gland. Korean J Pathol. 2013 Feb;47(1):36-43.
•Hwang MJ, Wu PR, Chen CM, Chen CY, Chen CJ. A rare malignancy of the parotid gland in a 13-year-old Taiwanese boy: case report of a mammary analogue secretory carcinoma of the salivary gland with molecular study. Med Mol Morphol. 2013 Aug 18.
•Knezevich SR, Garnett MJ, Pysher TJ, et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 1998;15:5046–5048.
•Makretsov N, He M, Hayes M, et al. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer. 2004;40:152–157.